Classical descriptions of tumor physiology suggest two origins for tumor hypoxia; steady-state (diffusion-limited) hypoxia and cycling (perfusionmodulated) hypoxia. Both origins, primarily studied and characterized in murine models, predict relatively small, isolated foci or thin shells of hypoxic tissue interspersed with contrasting oxic tissue. These foci or shells would not be expected to scale with overall tumor size since the oxygen diffusion distance (determined by oxygen permeability and tissue oxygen consumption rate) is not known to vary dramatically from tumor to tumor. We have identified much larger (macroscopic) regions of hypoxia in rat gliosarcoma tumors and in larger human tumors (notably sarcomas and high-grade glial tumors), as indicated by biochemical binding of the hypoxia marker, EF5. Thus, we considered an alternative cause of tumor hypoxia related to a phenomenon first observed in window-chamber tumor models: namely longitudinal arteriole gradients. Although longitudinal arteriole gradients, as originally described, are also microscopic in nature, it is possible for them to scale with tumor size if tumor blood flow is organized in an appropriate manner. In this organization, inflowing blood would arise from relatively well-oxygenated sources and would branch and then coalesce to poorly-oxygenated outflowing blood over distances much larger than the length of conventional arterioles (multi-millimeter scale). This novel concept differs from the common characterization of tumor blood flow as disorganized and/or chaotic. The organization of blood flow to produce extended longitudinal gradients and macroscopic regional hypoxia has many important implications for the imaging, therapy and biological properties of tumors. Herein, we report the first experimental evidence for such blood flow, using rat 9L gliosarcoma tumors grown on the epigastric artery/vein pair.
Introduction
Hypoxic tumor regions (reduced oxygen content compared to normal tissue) are thought to arise by two principal mechanisms.
Thomlinson and Gray first predicted static, diffusion-limited tumor hypoxia based on their findings that necrosis was found at the center of tumor tissue cords in human bronchial carcinomas exceeding 300-400 µ diameter [1] . The width of the annulus of viable tissue in these cords was consistent with the predicted oxygen diffusion distance [2] . A second mechanism for the production of hypoxia, described as cycling or perfusion-modulated, was predicted by J. Martin Brown in 1979 [3] . His hypothesis was confirmed a decade later by
Trotter and colleagues using dye-mismatch experiments [4] .
In these experiments, two blood perfusion markers, Hoechst 33342 and DiOC7, were injected into tumor-bearing mice.
Both markers bound to the DNA of exposed cells but could be differentiated by their fluorescence wavelength. Both dyes were found to label the walls of the same tumor vessels when injected simultaneously. However, when the dyes were injected at times separated by about 20 minutes, occasional individual vessels were found that showed binding of only one of the two dyes [4, 5] . This was interpreted to mean that blood flow was cycling on-and-off in the mismatched vessels. Subsequently, Dewhirst and colleagues demonstrated several subtleties to this scenario in tumor 'window chamber' models, including the possibilities of blood flow reversal and large local variations in hematocrit for individually monitored vessels [6] [7] [8] . Currently, there are no alternative methods to the dye-mismatch technique to distinguish diffusion-limited versus perfusion-modulated hypoxia, and to our knowledge this has not been investigated in large tumors. Additionally, DNA-binding dyes cannot be used in humans and the dyes themselves have been shown to be vasoactive [4] . Thus, new methods are constantly being sought that could identify perfusion-modulated hypoxia, preferably with application to humans. For example, Krishna and colleagues have suggested the use of EPR-based assays to measure cycling hypoxia directly -however, these methods are not yet scaleable to use in large human tumors - [9] see [10] for review.
Thus, while widely assumed to be of prominent importance, there is no direct evidence for perfusion-modulated hypoxia in human tumors [8, 11, 12] .
EF5 is a 2-nitroimidazole that is differentially metabolized by hypoxic compared with aerobic cells, forming macromolecular adducts that can be detected by monoclonal antibodies. This enables the use of EF5 as a 'hypoxia marker' and we have developed quantitative immunohistochemical (IHC) techniques to allow EF5 adducts to be interpreted as absolute tissue oxygen partial pressure -for review see [13] . Using these methods, we made an initial characterization of EF5 binding in 9L gliosarcoma tumors grown as epigastric pedicles [14] . This site of tumor growth has the property that the tumor vasculature arises almost entirely from a single source, the epigastric artery-vein pair (see description in methods). In contrast to their relatively oxic characteristic (uniformly low EF5 binding) when grown intracranially, 9L epigastric pedicle tumors were found to have highly heterogeneous hypoxia, both within and between tumors, as measured by EF5 binding [14] . 9L subcutaneous tumors have similar variability in extent and degree of hypoxia and we showed, for the first time in a tumor model, that intertumoral heterogeneity in radiation response could be predicted by EF5 binding [15] . This has been recently expanded to include an 18 F-labelled, non-invasive EF5 binding assay [16] . In some of these tumors, we found regions of high EF5 binding that extended over dimensions of much greater than 1 mm [17] . At the time, this was considered to be unexpectedly large, since the oxygen diffusion distance is typically of the order of 125-175 microns [1] . Thus viable cells (essential for EF5 metabolism)
should not exist beyond approximately 150 micrometers from the nearest blood vessel, and both current models for hypoxia predict relatively small zones of hypoxia (see Figure 1a) . At the time, we interpreted the macroscopic regions of hypoxia (MRH) as arising from some combination of diffusion-limited and perfusion-modulated hypoxia -for example, it was possible that cycling blood flow was occurring in large groups of vessels, though this has not been demonstrated experimentally and would be difficult to explain physiologically.
MRH were also found in high-grade sarcoma and glioma tumors from human patients given EF5 [18, 19] . In these cases, vessels were found within the hypoxic regions but an independent blood-flow measurement was not possible. EF5 binding can be assessed on a quantitative, analog scale, so we developed imaging algorithms to compute the gradients of EF5 binding away from individually identified vessels, grouped by their perivascular pO 2 . Unexpectedly, both positive and negative gradients were found, with averages over all observed vessels near zero, irrespective of the perivascular pO 2 . We hypothesized that such averaging might be possible if the overall tumor blood flow was organized to provide extended serial flow from well oxygenated inflow to poorly oxygenated outflow, and that these flow patterns were mixed spatially. This was termed the DIVOB model (differentiation of inflowing versus outflowing blood - [20] ).
Note the contrast between this postulated serial blood flow in tumors compared with the countercurrent parallel arterio-venous flow of vessels in normal tissue.
Our central hypothesis is that it is impossible to maintain the simple structure, illustrated in Figure 1a , for large tumors. 
Experimental procedures

Tumor Initiation
All procedures were approved by the IACUC committee of the University of Pennsylvania. 9L gliosarcoma cells were originally obtained from Dr. Ken Wheeler. They have been routinely tested and found free of mycoplasma and rat pathogens. The 9L epigastric pedicle model was described in 1995 [14] . Briefly, two sutures are placed around the epigastric artery-vein pair approximately 10 mm peripheral to its junction with the femoral artery-vein. Both sutures were tightened to occlude blood flow. Tumor source material, in the form of small tissue pieces (3-6 mg) were stored frozen in liquid nitrogen. A thawed tumor piece was tied to the more central suture, and the vessel-pair cut between the sutures. This process duplicated the original pedicle models of Gullino [21] , but for a spontaneous tumor growing and overtaking an existing artery-vein pair it seemed that the tumor would cause neither complete occlusion of blood flow nor the severing of the vessels. Thus, the tumor-initiating process was modified by simply tying the tumor piece onto the epigastric vessel pair (traversing model). An encircling suture was doubleknotted to ensure a stable location on the vessel, but not tied tightly enough to occlude blood flow. The tumor piece was then tied in place over the first knot. A drop of antibiotics was added, the fat pad replaced over the tumor and the access wound closed with surgical clips. Typically, the site of the original knot was identifiable by ultrasound even after substantial growth of the tumor to its experimental size (1-2 g), over a period of 2-3 weeks. The tumors will also grow at this site if the tumor piece is attached to the vessels using a surgical grade of superglue.
Immunohistochemistry
On the day prior to tumor collection, hair near the tumor was removed by Nair®. The next day the skin was marked to indicate Unauthenticated Download Date | 4/13/17 7:32 AM Figure 1a . Depiction 
Irradiation
Some animals were administered an X-ray dose of 17 Gy to half of the tumor, using a custom 'D'-shaped collimator attached to the small-animal-radiation-research-platform (SARRP) developed by Dr. Wong and colleagues at Johns Hopkins University [25] , now marketed by Xtrahl. The tumor was collected 45 minutes following irradiation.
Tumor Collection and Immunohistochemistry
At the time of tumor collection, the isoflurane concentration was increased to a surgical plane, and the tumor was removed, while retaining the marked skin portion to preserve orientation. The tumor was cradled in a stainless-steel rectangular container (ID ~ 25mm x 25mm x 30 mm; using threads passing back and forth through tiny holes in the walls of the container) in the same orientation as was observed in vivo. The block was then filled with molten (~40°) 3% low melt agarose and the container held on ice until solidification of the agarose. After removal of the threads, the agarose block was removed, frozen on an aluminum block cooled by dry-ice, then stored at -75°. The surface of the frozen agarose block was also marked so that the overall orientation of the tumor could be maintained.
Tissue Sections and Staining
The location of the knot used to tie on the originating tumor piece was known fairly accurately for tumors assessed by ultrasound, but could only be guessed as being close to the maximum diameter for most tumors. Thus the middle third of the tumor was sectioned in its entirety, saving four each 10 micron sections every two mm. The saved sections preceding the knot, including the knot, and after the knot were then processed for IHC and imaging. In order to preserve the blood-flow dyes (Hoechst 33342, DiOC7 or Dextran), the sections had to be imaged before fixation or immunohistochemical (IHC) processing, since the initial dye localization is not stable in the presence of aqueous or other solvents. Thus slides were dried on a warm-plate (37°) in the dark immediately following sectioning. In our experience this precludes the use of paraformaldehyde fixation in order to maintain the ability to accurately quantify EF5 binding. Between the alternatives of graded ethanol (70%, 85%, 100%; 5 minutes each at 0°) versus acetone fixation (5 minutes at 0°), we found that either was acceptable for EF5 binding but assessment of CD31 required graded ethanol (data not shown). Thus after imaging the entire sections for Hoechst 33342 or DiOC7 (or dextran if included), the sections were fixed in graded ethanols, and dual stained for EF5 and CD31 (the latter if required to identify all vessels). None of the plasma markers were retained after fixation, so wavelengths were not limiting for anti-CD31 (primary; BD Pharmingen mouse-anti-rat # 550300 3 µg/ml; secondary Alexa 488 goat anti-mouse) or anti-EF5 (Cy5 direct-conjugated the major axis of the tumor (along the direction of the epigastric vessels) and a second line at right angles marking the apparent maximum diameter of the tumor. Animals were anesthetized using isoflurane in medical air, at a concentration (typically 1.5 -2.5%) that maintained consistent breathing rates of about 60/minute. Animals were placed supine on a warmed heating pad and temperature was monitored with a rectal thermometer. All drugs were administered by intravenous injection using an in-dwelling tail catheter. Animals received EF5 (30 mg/kg) at -180 minutes (all times with respect to tumor collection which was considered to be time 'zero'), Hoechst 33342 (15 mg/kg) at -30 minutes and DiOC7 (0.15 mg/kg) at -5 minutes. Hoechst 33342 and EF5 were mixed at 200x and 100x, respectively, in 5% dextrose + 2.5% ethanol. Although DiOC7 has been administered to mice using a formulation of 100% dimethylsulfoxide [4] , this was found to be toxic for rats (unpublished data). Thus, we formulated the DiOC7 (at 600x) in 50% glycerol with 10% ethanol. This appeared to have the least physiological impact (tail straightening, or breathing change on injection -for example compared with a PEG formulation). Some animals were also assessed by a macromolecular plasma marker; tetramethyl rhodamine labeled dextran 75K (Invitrogen).
Dynamic Contrast-Enhanced (DCE) MRI
DCE/MRI was performed on a 9.4T horizontal bore magnet interfaced to a Varian Direct drive console. Under isoflurane anesthesia, the animal was placed in a custom-designed trough and rectal temperature was used to monitor the core body temperature. Additionally, a respiratory pillow was attached under the abdomen to measure the respiratory rate of the animal.
A vitamin E capsule was fixed on the skin (with superglue) in the proximity of the tumor for ease of identification of the tumor on MRI. A 24 gauge catheter was inserted into the tail vein and connected to plastic tubing for injection of the MRI contrast agent. The animal holder was then placed inside a 70 mm diameter transmit-receive volume coil such that the tumor was at the center of the coil. The coil was inserted in the magnet and the body temperature and respiration were monitored using a MRI compatible physiological monitoring device (SA Instruments, NY). The animal's body temperature was controlled by blowing warm air through the bore of the magnet. After initial localizer images, gradient echo images were acquired in the sagittal plane to localize a single 2mm thick section so as to include both the tumor as well as a major artery. The T1 of the tumor was measured using a TOMROP sequence as detailed elsewhere [22] . DCE-MRI was then performed at this slice section using a T1-weighted saturation recovery gradient echo imaging sequence (TR = 8 ms , TE = 2.75 ms) with a temporal resolution of about 4 s per image. After initial baseline images, a bolus of 300 microliters Gd-DTPA (0.2 mM) was injected while the images were being acquired for a total of 10 minutes. The signal intensity-time curves were converted into contrast agent concentration-time curves using the measured T1 relaxation values on a pixel-bypixel basis. The arterial input function (AIF) was measured from the arteries proximal to the tumor. We used the shutter-speed Unauthenticated Download Date | 4/13/17 7:32 AM each nuclear fragment, the intensity of EF5 binding and gH2AX
intensity was recorded in a 5x5 pixel area (100 square microns).
There were typically ~3000 partial nuclei per 10x field.
Results
We are not marked by these dyes may indicate a lack of perfusion but also the absence of drug, due to consumption. Since the perfusion dyes are themselves known to be vasoactive [4, 29] , an additional concern was that there was essentially no blood flow in MRH due to infarcts occurring during the experiment.
Thus we investigated various macromolecular dyes that could be injected just before tumor collection and therefore would demonstrate blood flow. Due to the relative infrequency of MRH and the high cost of the labeled markers, this turned out to be a complex task, especially since blood vessels tend to collapse during the process of tumor collection, making the amount of dye observable in the remaining blood negligible. Typically, agents such as Hoechst 33342 label several cell layers away from the vessel lumen, yet the vessels are observed as slits, with no lumen. Our general findings were that labeled rat antibodies and heterostarch both easily equilibrated with the tissue in regions of MRH (low level fluorescence throughout) thus making co-localization with vessels impossible to quantify. However, it was found that a charge-neutral dextran (75K) labeled with tetramethylrhodamine marked vessels that were not labeled by Hoechst 33342 (Figure 3 ).
MRH were first observed and the presence of ELG postulated based on detailed quantification of EF5 binding in small surgical biopsies of large human tumors [20] . A key observation in this report was that of both positive and negative gradients of EF5 binding away from individual vessels. This was thought to imply mixing of inflowing, oxygen rich, and outflowing, oxygen poor blood in nearby vessels. Due to the computational requirements of these measurements, and the availability of tissue from surgical biopsies, only tiny portions of human tumors had previously been assayed by these methods. Thus it was of interest to perform such studies on whole tumor cross-sections ELK3-51 primary). As previously introduced by our lab [13] , we prevent interaction of the goat anti-mouse secondary for CD31 with anti-EF5 antibodies using a short paraformaldehyde fixation after CD31 secondary staining (4%, 20 minutes, 0° followed by 3 rinses with PBS containing 0.3% tween 20). Overall stability of the antibodies was additionally maintained post-staining by storing the stained slides in PBS with 1% paraformaldehyde.
This allows imaging over a time that can be extended to several weeks [13] . Conversely, the section-containing slides could be stored at -80° in dessicant-containing storage tubes for several months before initiation of the staining and imaging process.
In our hands, staining for gH2AX requires an initial paraformaldehyde (pF) fixation, so it was necessary to use adjacent sections that were not pre-dried for this marker. Slides were fixed in 4% pF for 1 hr at 0°, and then additionally fixed in 70% ethanol overnight to gain access to DNA-associated antigens -this was in agreement with other DNA-associated events such as BrdUrd incorporation or TUNEL assay of apoptosis [26] . Staining for gH2AX was then accomplished using the Millipore 05-636 anti-gH2AX antibody (20 µg/ml), followed by staining for EF5 as per the above dual-stain procedure.
Images were made using a Nikon Eclipse 800 microscope, coupled to a 12-bit cooled CCD camera (Photometrics Quantix).
The camera and automatic stage (Ludl) were controlled by IPLab algorithms developed by one of the authors (CK). Images were converted to 8 bit tif files without modification of the contrast and assembled and analyzed using MATLAB. All algorithms were developed by one of the co-authors (KWJ). Whole-tumor cross-sections were usually assessed using a 4x objective (3mm x 2mm field) whereas smaller regions were quantified using a 10x objective (1.2mm x 0.8mm field). As we have described previously, a separate collage of fields of each section was made, as required, for plasma marker(s), EF5, CD31 (or gH2AX ), and then the section was flooded with Hoechst 33342 dye and re-imaged, which labels the nuclei of all intact cells (only a low level background fluorescence is seen in necrotic areas).
This 'Flooded Hoechst' image (FH) was used as a tissue mask for any subsequent quantification. This should not be confused with the Hoechst used as a blood flow marker, administered just before tumor collection. Image analysis of EF5 binding and gH2AX intensity was done quantitatively using an analog scale, whereas the other markers were assessed in binary fashion using appropriately derived background and maximum intensity signals.
gH2AX Analysis and Quantification
Imaging at low resolution (10x objective) provides a measure of whole-nucleus Ab detection of gH2AX , not individual foci or their relative variation in size [27] . Using MATLAB techniques similar to those quantifying Ki67 expression [28] , the flooded Hoechst images were used to define the spatial coordinates of each nucleus. Note that for 10 micron thick sections, most nuclei will not be observed in their entirety. Thus, the observed 'nuclei' should really be regarded as nuclear fragments, and have a considerable range of sizes. Using the coordinates for 
Figure 4. Panel a: 4x6 10x field of 5mm x 8mm epigastric tumor cross-section. Vessels are identified (light green) and contours formed around each vessel (5 contours, each separated from the next by 20µ) -the paths between the contours are pseudocolored white through increasingly dark grey. At the observed resolution of this image, only the innermost (white) path is clearly distinguished. Black pixels contain no nuclear stain, and blue areas are more than 100 µ from the nearest vessel. Average EF5 binding is calculated for the path between each pair of contours, and gradient of EF5 binding computed for each vessel (see reference 20). Panel b: Same region of tumor. EF5 binding has been converted to color-coded levels of oxygenation (green, 75-24 mm of Hg, physiological oxia; dark green, 24-7.5 mm of Hg, mild hypoxia; red, 7.5-2.4 mm of Hg, moderate hypoxia; orange, 2.4-0.75 mm of Hg, severe hypoxia). Vessels with the largest positive EF5 gradients are colored white, while those with largest negative EF5 gradients are colored magenta. Note that this tumor appears to have 'normal' diffusion-limited hypoxia. Thus, mixed positive and negative EF5 gradients are not directly linked with MRH but rather appear to be caused by the geometry of blood flow in large tumors.
blood flow paths, and the mixing of inflowing and outflowing blood are simply a requirement for large tumors, and need not cooperate to produce MRH.
It is clearly very time-consuming to investigate, by immunohistochemistry, many large tumors especially with such a large number of potential stains and analyses. We thus began an investigation to determine whether it might be possible to
predict MRH based on the non-invasive perfusion-imaging technique Dynamic Contrast Enhanced Magnetic Resonance
Imaging (DCE-MRI - [22] [23] [24] ). Since the parameter K trans combines aspects of both blood flow and vascular permeability [22] the overall concern was that MRH would contain highly permeable vessels that would be interpreted similarly to regions with vessels having high blood flow. In the first two tumors studied with this method, this concern was confirmed ( Figure 5 ). Table 1 (Table 1) .
That is, high EF5 binding is associated with low X-ray-induced DNA damage, and vice versa.
Discussion
In this report we have demonstrated the presence of MRH in 1-2g 9L gliosarcoma tumors grown with the epigastric arteryvein pair as their primary blood supply. The presence of MRH in this model recapitulates our previous observations in (much larger) human high-grade sarcomas and brain tumors (GBM) [18] [19] [20] . We suggest that the nature of blood flow in the 9L epigastric model lends itself to the production of very long paths of blood flow from the arterial inflow to venous outflowindeed, this process appears geometrically inevitable. The ELG form simply because arterial inflow and venous outflow are not paired in tumors. What we did not completely appreciate in our first attempts to define such gradients [20] was their universal nature in all macroscopic tumors -however, it is only in tumors of greater than or equal to the size studied here that the impact of the gradients clearly distinguishes itself from that occurring in smaller tumors. Interestingly, in some of the first dye-mismatch experiments using murine tumors, Chaplin and colleagues noted that the intensity of the dyes varied dramatically from vesselto-vessel and they suggested that this could be due not only to variations in vessel size, but also drug consumption along the length of the vessels. However, this required analog rather than binary image analysis techniques that were beyond the power of computers then available [30] . Table 1 ). been measured independently (e.g. both can be done using dynamic and static PET measurements with labeled EF5 - [32] ) no relationship has been obvious. The issue of scale has generally been ignored. Thus, the cover of a recent issue of The
an immunohistochemical (IHC) section, cut from the same region of tumor that is also seen on the MRI images (lower panels). The IHC section is 10 microns thick whereas the MRI voxel depth is 2 mm. In the upper panel EF5 binding, as a surrogate for tissue hypoxia, is shown in red, all vessels as identified by anti-CD31 antibody in green and labeled vessels, marked by an intravenous injection of DiOC7 before the tumor was removed, in blue. The region of very high density vessels at the lower edge of the section is skin. An image of all intact nuclei (measured by flooding the section with Hoechst 33342) showing a substantial region of partial necrosis in the central lower half of the tumor, indicated by the white polygon; N). The MRI panels (left) show an axial section (contrast enhanced T1 weighted image; P) of the animal (tail to the left and tumor in lower right). DCE MRI was performed using the Shutter Speed
International Journal of Radiation Oncology, Biology, Physics depicted a tumor as a large apple, with necrotic core and successive layers of better oxygenation towards the periphery [33] . This type of structure would be ideal from an imaging or therapeutic standpoint, but is not realistic physiologically [34] .
The critical issue to be addressed is whether MRH and/or ELG represent new, clinically relevant phenomena, or whether they could be caused by a new manifestation of cycling hypoxia.
Of fundamental importance is whether EF5 binding is accurately What appears to be incontrovertible is that extended longitudinal blood flow gradients must exist in these tumors due to their blood flow source (Figure 1c ). This represents the logical extension of a phenomenon first described by Dewhirst in window chamber models (longitudinal arteriole gradients) [7] . However, diffusion-limited hypoxia does not require low blood flow, and in cases where both blood flow and hypoxia have of the total number of tumors studied, it could also have been possible that we were observing cycling blood flow on a massive scale. Alternatively, blood flow could have been present shortly after induction of anesthesia, when the EF5 was injected, and then ceasing shortly thereafter. Such local infarcts are often observed in human GBM tumors [40] . Labeling of such vessels by TRITC-dextran suggests a different mechanism, but all of the perfusion markers can only image perfusion at a single time.
In the interpretation offered by ELG, reactive drugs are simply consumed along the path of blood flow. If this interpretation were correct, it would mean that other rapidly metabolized drugs might also be consumed along the path of blood flow. Thus, both diffusion and perfusion problems could limit the effectiveness of therapeutic drugs. Although we have only looked at this in preliminary fashion, it has been found that adriamycin (which can also be detected by fluorescence microscopy) has very limited access to the tissue of these tumors (data not shown). and K trans [42] . More recent analysis that has re-evaluated these patients has suggested an even better relationship between taui and outcome, consistent with the findings of the current study (Quon and Poptani, unpublished data).
Conclusions
(1) MRH is found in 9L epigastric tumors and is associated with an apparent perfusion deficit that involves extended longitudinal blood flow gradients on an enormous scale.
(2) In view of the singular source of blood flow (epigastric arteryvein pair) such extended blood flow gradients are predicted by not been determined. Dewhirst has suggested that temporal changes in hematocrit might prove an alternative explanation, since resumption of flow after stoppage is very problematic [6] .
However, it is difficult to see how variable hematocrit would be compatible with the dye mismatch experiments and there has never been any indication that blood flow could stop and then resume in multiple coordinated vessels.
A key new finding in the present studies is the development of whole cell gH2AX as a short term indicator of hypoxia (effective only during the radiation exposure). The only data from the literature on this subject is from Dr. Peggy Olive's group. It
was the first to demonstrate that hypoxic areas (measured by coincident binding of pimonidazole) had increased damage in the absence of radiation (similar to earlier work looking at induction of p53 - [35] ). However, their studies looked for a relationship between tumor cell cure and residual gH2AX foci 24 hr following radiation [36] . In contrast, our studies have emphasized initial damage production as modified by the well-known oxygen effect. Olive's group has also published in vitro data that agree with our value for the oxygen enhancement ratio for gH2AX
formation (~4 -data not shown).
We have looked in preliminary fashion at the relationship between gH2AX and EF5 staining in two other tumor types -9L subcutaneous (shoulder) and R3230 mammary carcinoma, the latter grown orthotopically (mammary fat pad). In all cases investigated to date, an inverse relationship has been found. are not localized to vessels in regions of MRH. Indeed, this finding was initially interpreted to mean that MRH tissue was not perfused, but raised the problem of how EF5 could gain access for the observed labeling. Our finding that vessels within MRH are labeled by TRITC-labeled dextran (overall neutral charge)
but not other high molecular mass markers can reasonably be interpreted to mean that many vessels within MRH are both perfused and highly permeable.
b) The presence of MRH and the attendant vascular permeability that occurs randomly in hypoxic tumors provides a possible explanation for the co-operative therapeutic importance of both hypoxia and interstitial tumor pressure, described for cervix cancer by Fyles, Milosavic and colleagues [38, 39] . It may be possible to exploit this permeability to Unauthenticated Download Date | 4/13/17 7:32 AM simple geometrical considerations (see Figure 1) . However, there is no need for a singular blood supply for such gradients to exist.
As such the 9L epigastric model may be regarded as a basic unit that is repeated in larger tumors, with multiple blood sources 
